Related by context. All words. (Click for frequent words.) 81 mRCC 77 HER2 positive metastatic breast 76 metastatic RCC 76 recurrent NSCLC 75 stage IIIB 74 temsirolimus 74 renal cell carcinoma 74 vandetanib 74 sorafenib Nexavar 74 metastatic colorectal cancer 74 leukemia AML 74 axitinib 74 NSCLC 74 Amrubicin 74 FOLFIRI 73 advanced NSCLC 73 Doxil ® 73 IV NSCLC 73 unresectable 73 trabectedin 73 chronic lymphocytic leukemia CLL 73 mCRC patients 72 relapsed refractory multiple myeloma 72 docetaxel chemotherapy 72 recurrent glioblastoma multiforme 72 sunitinib 72 sorafenib 72 dacarbazine 72 erlotinib Tarceva ® 72 basal cell carcinoma BCC 72 dasatinib Sprycel ® 72 refractory multiple myeloma 72 leukemia CLL 72 gastrointestinal stromal tumors 72 pegylated liposomal doxorubicin 72 relapsed ovarian cancer 72 bevacizumab Avastin 72 chlorambucil 72 non squamous NSCLC 72 heavily pretreated 72 imatinib Gleevec ® 72 castration resistant prostate cancer 72 fallopian tube carcinoma 72 neoadjuvant chemotherapy 72 Nexavar sorafenib 72 gastrointestinal stromal tumors GIST 72 gastrointestinal stromal tumor GIST 71 FOLFOX6 71 prostate cancer HRPC 71 Torisel 71 bevacizumab Avastin ® 71 metastatic melanoma 71 pancreatic adenocarcinoma 71 heavily pretreated patients 71 metastatic castration resistant 71 Irinotecan 71 receptor tyrosine kinase inhibitor 71 bendamustine 71 EGFR TKI 71 metastatic malignant melanoma 71 stage IIIB IV 71 gefitinib Iressa 71 mCRC 71 relapsed MM 71 malignant pleural mesothelioma 71 Lenalidomide 71 HRPC 71 Erlotinib 71 relapsed multiple myeloma 70 diagnosed multiple myeloma 70 chemoradiotherapy 70 cetuximab Erbitux R 70 vinorelbine 70 hormone refractory prostate cancer 70 metastatic malignant 70 resectable 70 mTOR inhibitor 70 refractory AML 70 cell lymphoma CTCL 70 decitabine 70 stage IIIb IV 70 sorafenib Nexavar ® 70 imatinib resistant 70 plus gemcitabine 70 carboplatin paclitaxel 70 VELCADE melphalan 70 KRAS wild 70 pancreatic NET 70 mapatumumab 70 castrate resistant prostate cancer 70 amrubicin 70 platinum refractory 70 sunitinib malate 70 melphalan prednisone 70 cetuximab Erbitux ® 70 recurrent GBM 70 resistant ovarian cancer 70 erlotinib 70 metastatic GIST 70 nonmetastatic 70 cilengitide 70 Dasatinib 70 metastatic hormone refractory 69 Acute Myeloid Leukemia AML 69 TEMODAL 69 Neoadjuvant 69 refractory NSCLC 69 standard chemotherapy regimen 69 relapsed refractory 69 recurrent glioblastoma 69 trastuzumab 69 lymphoma CTCL 69 Pemetrexed 69 Fludara 69 superficial bladder cancer 69 cutaneous T cell 69 Follicular Lymphoma 69 biologic therapy 69 Taxotere ® 69 hepatocellular carcinoma HCC 69 pegylated interferon alpha 69 idarubicin 69 pomalidomide 69 HER2 positive 69 nab paclitaxel 69 FOLFOX4 69 topotecan 69 unresectable stage 69 metastatic colorectal 69 metastatic renal cell 69 ribavirin RBV 69 Gemcitabine 69 refractory metastatic 69 HER2 positive breast cancer 69 regorafenib 69 Gleevec resistant 69 docetaxel 69 5FU 69 lupus nephritis 69 neoadjuvant therapy 69 fluoropyrimidine 69 metastatic HRPC 69 refractory CLL 69 prostate cancer CRPC 69 mycophenolate mofetil 69 pertuzumab 69 Ceflatonin 69 docetaxel Taxotere 69 Castration Resistant Prostate Cancer 69 SCCHN 69 refractory ovarian cancer 69 relapsing multiple sclerosis 69 multiple myeloma MM 69 thalidomide Thalomid 69 Aflibercept 69 CHOP chemotherapy 69 docetaxel Taxotere ® 69 prostate cancer mCRPC 69 evaluating tivozanib 68 tumors GIST 68 gemcitabine chemotherapy 68 hepatocellular cancer 68 elacytarabine 68 bevacizumab 68 indolent NHL 68 gemcitabine carboplatin 68 gemcitabine Gemzar 68 cediranib 68 phase IIb clinical 68 Gleevec imatinib mesylate 68 glioblastoma multiforme GBM 68 azacitidine 68 cabazitaxel 68 TKI therapy 68 gemcitabine 68 Sorafenib 68 metastatic prostate cancer 68 metastatic CRC 68 metastatic castrate resistant 68 metastatic gastric 68 dasatinib Sprycel 68 Bevacizumab 68 cisplatin chemotherapy 68 chemotherapy cisplatin 68 Herceptin trastuzumab 68 Bortezomib 68 ZACTIMA 68 taxane therapy 68 paclitaxel carboplatin 68 refractory acute myeloid 68 monotherapy 68 nucleoside analog 68 BARACLUDE ® 68 BAY #-# 68 pemetrexed 68 nonsmall cell lung cancer 68 temozolomide 68 alkylating agent 68 biliary tract cancer 68 invasive candidiasis 68 dacarbazine DTIC 68 recurrent ovarian cancer 68 sunitinib Sutent 68 neoadjuvant 68 anthracycline taxane 68 SCH # 68 ErbB2 positive 68 pazopanib 68 nilotinib 68 cytotoxic chemotherapy 68 Fludara ® 68 TORISEL 68 GW# [003] 68 untreated multiple myeloma 68 remission induction 68 hepatic metastases 68 Trastuzumab 68 Cloretazine 68 metastatic pancreatic cancer 67 taxane chemotherapy 67 interferon alfa 2a 67 colorectal liver metastases 67 trastuzumab Herceptin ® 67 acute leukemias 67 advanced hepatocellular carcinoma 67 MabCampath 67 non squamous 67 IRESSA 67 YONDELIS 67 Myelodysplastic Syndrome MDS 67 daunorubicin 67 Velcade bortezomib 67 mutated KRAS 67 relapsing remitting multiple sclerosis 67 irinotecan chemotherapy 67 chemoradiation 67 tocilizumab 67 ixabepilone 67 EGFR inhibitors 67 Peginterferon 67 lymphoid malignancies 67 capecitabine Xeloda 67 posaconazole 67 placebo dexamethasone 67 non metastatic osteosarcoma 67 ovarian carcinoma 67 EGFR mutation positive 67 plus dexamethasone 67 sorafenib tablets 67 advanced metastatic renal 67 follicular lymphoma 67 liposomal doxorubicin 67 metastatic bladder 67 seminoma 67 EGFR expressing mCRC 67 Sutent sunitinib 67 Halaven 67 HBeAg positive patients 67 trastuzumab Herceptin R 67 fludarabine 67 refractory CTCL 67 gefitinib 67 fluorouracil 67 follicular lymphoma FL 67 Hodgkin lymphoma NHL 67 imatinib Gleevec 67 plus prednisone 67 cinacalcet 67 sunitinib Sutent ® 67 Tarceva erlotinib 67 FOLFOX 67 EGFR tyrosine kinase inhibitors 67 KRAS mutant tumors 67 relapsed CLL 67 myelodysplastic syndrome MDS 67 hypomethylating agents 67 Epratuzumab 67 bone metastasis 67 HBeAg positive 67 NMIBC 67 radiation sensitizer 67 unresectable tumors 67 lumiliximab 67 BRAF inhibitor 67 estramustine 67 CLL SLL 67 docetaxel Taxotere R 67 Fludarabine 67 pancreatic neuroendocrine tumors 67 immunomodulatory therapy 67 glufosfamide 67 Cutaneous T 67 colorectal carcinoma 67 Surgical resection 67 metastatic kidney 67 Traficet EN 67 CANCIDAS 67 B CLL 67 Rituxan rituximab 67 metastatic breast cancer 67 vismodegib 66 Gemzar ® 66 adalimumab 66 adalimumab Humira 66 PegIntron 66 epithelial ovarian cancer 66 medullary thyroid cancer 66 alvespimycin 66 dasatinib 66 Voreloxin 66 leukemia ALL 66 alfa 2a 66 interferon alfa 66 rituximab refractory 66 preoperative chemotherapy 66 Tarceva TM 66 Aplidin 66 Jevtana 66 Paraplatin ® carboplatin 66 anti leukemic 66 Avastin bevacizumab 66 Temsirolimus 66 Metastatic Colorectal Cancer 66 RRMS patients 66 micafungin 66 Hepatocellular Carcinoma HCC 66 KRAS mutations occur 66 infusional 5-FU/LV 66 advanced unresectable 66 refractory chronic myeloid 66 sustained virological response 66 DMARD 66 cancer mCRC 66 liver metastases 66 TTF Therapy 66 Pertuzumab 66 follicular NHL 66 IV melanoma 66 rituximab 66 Chronic Lymphocytic Leukemia 66 Pegylated Interferon 66 stage IIIb 66 cytotoxic therapy 66 dose cytarabine 66 Peginterferon alfa 2b 66 Annamycin 66 Taxotere R 66 antibody MAb 66 HER2 overexpression 66 ritonavir boosted 66 clinically localized prostate 66 standard chemotherapy regimens 66 proteasome inhibitor 66 paclitaxel Taxol 66 neratinib 66 Gleevec imatinib 66 HGS ETR1 66 5-FU/LV 66 chemoresistant 66 TACE 66 HBeAg negative 66 histologically confirmed 66 CIMZIA ™ 66 oblimersen 66 peginterferon alfa 2a 66 Flu Cy 66 Mitoxantrone 66 Xanafide 66 crizotinib PF # 66 cetuximab 66 pan HDAC inhibitor 66 goserelin 66 metaglidasen 66 familial amyloidotic polyneuropathy FAP 66 autoantibody positive 66 concurrent chemoradiation 66 SUTENT 66 Platinol 66 refractory chronic lymphocytic 66 bortezomib 66 FOLFIRI alone 66 adecatumumab 66 liposomal formulation 66 imatinib 66 bone metastases 66 CYT# potent vascular disrupting 66 tigecycline 66 adjuvant therapy 66 IV metastatic melanoma 66 free survival PFS 66 medically inoperable 66 APTIVUS r 66 bevacizumab Avastin R 66 cutaneous T 66 olaparib 66 prostate carcinoma 66 vemurafenib 66 Nexavar tablets 66 BR.# 66 LHRH receptor positive 66 galiximab 66 Platinol ® cisplatin 66 AVASTIN 66 telaprevir dosed 66 cisplatin gemcitabine 66 localized renal 66 Folfox 66 Capecitabine 66 vidofludimus 66 situ CIS 66 neoadjuvant treatment 66 pegylated interferon alfa 2a 66 PREZISTA r 66 Relapsed Refractory 66 imatinib therapy 66 elotuzumab 66 EOquin 66 HNSCC 66 Vectibix 66 Laquinimod 66 IMGN# 66 vinca alkaloid 65 Tamibarotene 65 tyrosine kinase inhibitor 65 interferon beta 1a 65 MAGE A3 ASCI 65 5 fluorouracil 65 inhibitor RG# 65 cell lung cancer 65 tumor recurrence 65 Revlimid lenalidomide 65 peginterferon 65 Akt inhibitor 65 OncoVEX GM CSF 65 TroVax ® 65 androgen independent 65 ACTEMRA TM 65 tanespimycin 65 MGd 65 xanthine oxidase inhibitor 65 nucleoside analogue 65 cytoreductive nephrectomy 65 nilotinib Tasigna ® 65 adjuvant radiation 65 hepatocellular carcinoma 65 vascular disrupting agent 65 prostate cancer CaP 65 eribulin mesylate 65 Hycamtin 65 breast carcinoma 65 tyrosine kinase inhibitor TKI 65 DFMO 65 Tavocept 65 Genasense ® 65 relapsed SCLC 65 rituximab Rituxan 65 docetaxel prednisone 65 cetuximab Erbitux 65 paclitaxel Taxol R 65 metastatic colorectal carcinoma 65 phase IIb study 65 INCB# [003] 65 HCV genotype 1 65 sipuleucel T 65 K ras mutations 65 Quinamed 65 Everolimus 65 gemcitabine cisplatin 65 Golimumab 65 vinca alkaloids 65 mitomycin 65 Proxinium TM 65 Blinatumomab 65 Vidaza azacitidine 65 imatinib mesylate 65 phase IIb trial 65 low dose cytarabine 65 XELOX 65 TYKERB 65 mTOR inhibitors 65 solid tumors 65 PEG IFN 65 epithelial tumors 65 histone deacetylase HDAC inhibitor 65 null responder 65 subcutaneously administered 65 biochemical relapse 65 Cyclophosphamide 65 Metastatic Prostate Cancer 65 oral Hycamtin 65 ximelagatran 65 panitumumab Vectibix 65 5 fluorouracil leucovorin 65 PROSTVAC VF 65 HuMax CD4 65 BCG refractory 65 Hsp# Inhibitor 65 Bezielle 65 Pazopanib 65 Gefitinib 65 bortezomib Velcade R 65 viral kinetics 65 IMA# 65 urothelial bladder cancer 65 Faslodex 65 myelodysplastic syndromes MDS 65 recurrent metastatic 65 depsipeptide 65 Rituximab 65 Elagolix 65 protease inhibitor PI 65 Pharmacokinetics PK 65 DAPT 65 cyclophosphamide methotrexate 65 Toxicities 65 ganetespib 65 Dapagliflozin 65 relapsing MS 65 5 FU leucovorin 65 Nilotinib 65 oral ridaforolimus 65 Mantle Cell Lymphoma 65 soft tissue sarcomas 65 Acute Myeloid Leukemia 65 calcineurin inhibitor 65 refractory metastatic colorectal cancer 65 pancreatic carcinoma 65 ribavirin therapy 65 unresectable liver cancer 65 Zolinza 65 Navelbine ® 65 BRIM2 65 gemcitabine Gemzar ® 65 teriflunomide 65 Paraplatin ® 65 small lymphocytic lymphoma 65 virus HCV protease inhibitor 65 brain metastases 65 unresectable locally advanced 65 systemic lupus erythematosus SLE 65 HSP# inhibitor 65 DOXIL 65 paclitaxel Taxol ® 65 Hormone Refractory Prostate Cancer 65 DLBCL 65 localized prostate cancer 65 acute coronary syndromes ACS 65 romiplostim 65 Pegasys plus Copegus 65 AA Amyloidosis 65 pegylated interferon alfa 65 Ozarelix 65 mitoxantrone 65 pegylated interferon alfa 2b 65 completely resected 65 irinotecan containing 65 bladder carcinoma 65 myelodysplastic myeloproliferative diseases 65 CLL 65 iniparib 65 metastatic colon cancer 65 systemic ALCL 65 ZOLINZA 65 GIST 65 ELACYT 65 capecitabine 65 eribulin 65 panobinostat 65 operable breast cancer 65 protein kinase inhibitor 65 resected pancreatic cancer 65 GvHD 65 T DM1 65 infliximab Remicade 65 acute myelogenous leukemia AML 64 PCa 64 metastatic NSCLC 64 bosutinib 64 Imatinib 64 PEGylated Fab fragment 64 basiliximab 64 Xeloda capecitabine 64 T2DM 64 ZYBRESTAT 64 Chronic Myeloid Leukemia 64 allogeneic stem cell 64 Decitabine 64 fosbretabulin 64 erlotinib Tarceva 64 locoregional disease 64 antiangiogenic therapy 64 5 Fluorouracil 64 liposomal amphotericin B 64 differentiated thyroid 64 perifosine 64 Cloretazine ® 64 demonstrated antitumor activity 64 lintuzumab 64 invasive aspergillosis 64 Darusentan 64 EGFR mutations 64 adriamycin 64 Renal Cell Carcinoma 64 CTAP# Capsules 64 eosinophilic asthma 64 Aptivus ® 64 CAELYX 64 temsirolimus Torisel ® 64 locoregional 64 HGS ETR2 64 cytokine refractory 64 colorectal cancer liver metastases 64 Romidepsin 64 assessing T DM1 64 Onrigin 64 interferon ribavirin 64 carboplatin 64 IIIB NSCLC 64 Glioblastoma Multiforme 64 Advanced Renal Cell 64 NOXAFIL 64 doublet chemotherapy 64 Natalizumab 64 lenalidomide Revlimid R 64 curative resection 64 Pegasys ® 64 Alocrest 64 pT2 64 Seliciclib 64 chemotherapeutic drug 64 partial remissions 64 evaluable 64 RoACTEMRA 64 Femara letrozole 64 Gliadel Wafer 64 Bosutinib 64 AQ4N 64 xenograft models 64 entinostat 64 rilonacept 64 ASA# 64 Diffuse Large B 64 alefacept 64 Ranibizumab 64 PKC# 64 refractory APL 64 Targretin 64 bortezomib Velcade 64 romidepsin 64 pegylated interferon 64 Patients Treated With 64 KRAS status 64 metastatic lung cancer 64 pegylated interferons 64 luteinizing hormone releasing 64 IFN α 64 transthyretin amyloidosis 64 ara C 64 palifermin 64 6 mercaptopurine 64 interferon gamma 1b 64 cytoreduction 64 HER2 negative 64 systemic lupus erythematosus 64 Carboplatin 64 acute promyelocytic leukemia APL 64 seliciclib 64 anti EGFR antibody 64 lapatinib Tykerb 64 R sorafenib tablets 64 PEGINTRON TM 64 Soft Tissue Sarcoma 64 NovoTTF 64 CBLC# 64 hormone refractory 64 DMARD therapy 64 CML CP 64 efalizumab 64 chemoradiation therapy 64 Degarelix 64 dexamethasone Decadron 64 follicular lymphomas 64 Malignant Melanoma 64 tyrosine kinase inhibitors 64 ELOXATIN 64 methotrexate MTX 64 PegIFN 64 urothelial carcinoma 64 Adjuvant chemotherapy 64 baminercept 64 recurrent malignant glioma 64 FOLFOX regimen 64 fluvastatin 64 hormone refractory metastatic prostate 64 Pralatrexate 64 Taxotere chemotherapy 64 bleomycin 64 trastuzumab DM1 64 Chronic Lymphocytic Leukemia CLL 64 secondary hyperparathyroidism 64 Zybrestat 64 chemotherapy docetaxel 64 Elitek 64 HER2 + 64 Acute Myelogenous Leukemia AML 64 Peginterferon Alfa 2a 64 papillary renal cell carcinoma 64 recurrent colorectal cancer 64 Ceplene/IL-2 64 dose escalation clinical 64 abacavir lamivudine 64 forodesine 64 Chronic Hepatitis C 64 Alemtuzumab 64 refractory colorectal cancer 64 Ambrisentan 64 gastrointestinal stromal tumor 64 CIMZIA TM 64 BEACOPP 64 ISEL 64 vincristine doxorubicin 64 anti TNF 64 Camptosar ® 64 lapatinib 64 trastuzumab Herceptin 64 comparator arm 64 OvaRex ® MAb 64 FluCAM 64 Intravenous CP 64 SPRYCEL ® 64 Daclizumab 64 adjuvant tamoxifen 64 abiraterone acetate 64 FOLPI 64 stage IIIA 64 Torisel temsirolimus 64 SIR Spheres 64 aflibercept VEGF Trap 64 denileukin diftitox 64 alpha 2a 64 refractory myeloma 64 cutaneous melanoma 64 riociguat 64 cholangiocarcinoma 64 adjuvant radiotherapy 64 NATRECOR R 64 castrate resistant 64 PsA 64 Ceftaroline 64 Phase Ib II 64 opioid induced constipation OIC 64 chemotherapy regimens 64 chemo radiotherapy 64 flutamide 64 nitazoxanide 64 peritoneal carcinomatosis 64 AKT inhibitor 64 palifosfamide 64 underwent surgical resection 64 immunoconjugate 64 APTIVUS R 64 grade cervical intraepithelial 64 mg/m2 dose 64 CR# vcMMAE 64 Tyrima 64 Telintra 64 etoposide 64 fallopian tube cancers 64 trans retinoic acid 64 EOquin TM 64 essential thrombocythemia ET 64 mitoxantrone plus 64 tipranavir ritonavir 64 HSCT 64 FTY# fingolimod 64 metastatic pancreatic 64 external beam radiotherapy 64 DMARDs 63 boosted protease inhibitor 63 abacavir Ziagen 63 enzastaurin 63 Naive Patients 63 Glufosfamide 63 ASCT 63 renal tumors 63 PEGylated interferon beta 1a 63 CsA 63 interferon therapy 63 PRT# 63 Navelbine 63 lenalidomide dexamethasone 63 Cell Lymphoma 63 non resectable 63 T#I [002] 63 antitumor activity 63 FOLFOX chemotherapy 63 AEG# 63 Tasigna nilotinib 63 anthracyclines taxanes 63 Hazard Ratio 63 chemotherapeutic agent 63 refractory indolent non 63 sirolimus eluting stent 63 Ranolazine 63 virologic failure 63 refractory cutaneous T 63 Certolizumab pegol 63 FUSILEV enhances 63 Interferon alfa 63 Newly Diagnosed Multiple Myeloma 63 caspofungin 63 CMV disease 63 interferon alfa 2b 63 squamous histology 63 dose dexamethasone 63 achieved sustained virological 63 3TC lamivudine Epivir 63 OPAXIO 63 Mipomersen 63 pain palliation 63 PEG interferon 63 tyrosine kinase inhibitors TKIs 63 Phase Ib study 63 previously untreated follicular 63 distant metastasis 63 Hodgkin lymphoma HL 63 chronic myeloid leukemia CML 63 huN# DM1 63 epirubicin 63 cell carcinoma RCC 63 KRAS mutation 63 Sym# 63 hepatorenal syndrome 63 BRIM3 63 virologic response 63 sorafenib Nexavar R 63 HCV SPRINT 63 Xeloda ® 63 Sanofi Aventis Taxotere 63 anthracycline containing 63 Nexavar ® 63 tumor xenograft models 63 VFEND 63 aflibercept 63 invasive bladder 63 CINTREDEKIN BESUDOTOX 63 myelofibrosis polycythemia vera 63 paclitaxel poliglumex 63 oxaliplatin Eloxatin 63 azacytidine 63 TBC# 63 vorinostat 63 antiarrhythmic drug 63 colon carcinoma 63 prostate cancer PCa 63 voriconazole 63 ancrod 63 HCV RESPOND 2 63 irinotecan doxorubicin oxaliplatin paclitaxel 63 anticancer therapy 63 chronic plaque psoriasis 63 intravesical instillation 63 Phase Ib clinical 63 Hycamtin ® 63 neovascular diseases 63 Multiple Myeloma MM 63 idiopathic pulmonary fibrosis IPF 63 PegIFN RBV 63 ER CHOP 63 DU #b 63 multi kinase inhibitor 63 glatiramer acetate 63 Ophena TM 63 prostate cancer AIPC 63 SHPT 63 stable angina 63 PXD# 63 Triapine 63 lung metastases 63 mycosis fungoides 63 Randomized Phase 63 Dacogen injection 63 Plicera 63 MyVax R 63 talabostat 63 CA4P 63 mertansine 63 Bevacizumab Avastin 63 HuMax EGFr 63 lopinavir r 63 relapsed AML 63 tumor shrinkage 63 Zevalin R Ibritumomab 63 acute GvHD 63 CCR5 antagonist 63 thromboembolic events 63 hepatitis C HCV 63 ABVD 63 Troxatyl 63 pT3 63 intravesical therapy 63 Noxafil 63 pediatric acute lymphoblastic 63 evaluable patients 63 IMC A# 63 OZURDEX ® 63 Enzastaurin 63 anti angiogenic agents 63 carcinoid tumors 63 Adalimumab 63 alpha 2b 63 GISTs 63 Peg IFN 63 CRp 63 APTIVUS 63 INCB# [001] 63 malignant ascites 63 thymalfasin 63 relapsed leukemia 63 multicentre randomized 63 Docetaxel 63 biochemical recurrence 63 haematological malignancies 63 idraparinux 63 anti angiogenic therapy 63 CoFactor 63 Allovectin 7 ® 63 Brentuximab Vedotin SGN 63 Pegasys peginterferon alfa 2a 63 terlipressin 63 PROSTVAC ® 63 Perifosine 63 systemic fungal infections 63 TO AVOID PREGNANCY WHILE 63 IRX 2 63 MYLOTARG 63 visilizumab 63 symptomatic BPH 63 evaluating Xcytrin 63 sodium glucose cotransporter 63 non metastatic resectable 63 ACZ# 63 Monotherapy 63 Erbitux cetuximab 63 prostate adenocarcinoma 63 postmenopausal osteoporotic women 63 humanized anti 63 hypercalcemia 63 humanised monoclonal antibody 63 evaluating REVLIMID 63 VIDAZA 63 severe neutropenia 63 Pegintron 63 PD LID 63 MIRCERA 63 Oral Fingolimod 63 LHRH analogues 63 zalutumumab 63 trabedersen 63 abiraterone 63 TNF Tumor Necrosis Factor 63 metastatic 63 Cell Lung Cancer 63 squamous cell carcinoma SCC 63 Copegus ribavirin 63 dose cohorts 63 HBeAg negative patients 63 efavirenz EFV 63 Eculizumab 63 DEB# 63 Romiplostim 63 Pfizer Sutent 63 virological failure 63 GRASPA ® 63 LEXIVA r 63 histologies 63 leukemia APL 63 relapsing remitting MS RRMS 63 metastatic disease 63 thymoma 63 Clofarabine 63 Metastatic 63 refractory gout 63 taxane 63 phase IIa clinical 63 cisplatin 63 immunotherapeutic agent 63 TNF inhibitor 63 Pivotal Phase III 63 Tocilizumab 63 PI3K inhibitor 63 Panzem R NCD 63 FOLOTYN ® 63 TELINTRA 63 metastatic androgen independent 63 BCR ABL inhibitor 63 ORENCIA ® 63 cytarabine 63 Telcyta